ID   S17A5_HUMAN             Reviewed;         495 AA.
AC   Q9NRA2; Q5SZ76; Q8NBR5; Q9UGH0;
DT   07-JUN-2004, integrated into UniProtKB/Swiss-Prot.
DT   07-JUN-2004, sequence version 2.
DT   10-MAY-2017, entry version 137.
DE   RecName: Full=Sialin;
DE   AltName: Full=H(+)/nitrate cotransporter;
DE   AltName: Full=H(+)/sialic acid cotransporter;
DE            Short=AST;
DE   AltName: Full=Membrane glycoprotein HP59;
DE   AltName: Full=Solute carrier family 17 member 5;
DE   AltName: Full=Vesicular H(+)/Aspartate-glutamate cotransporter;
GN   Name=SLC17A5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=11751519;
RA   Fu C., Bardhan S., Cetateanu N.D., Wamil B.D., Wang Y., Yan H.-P.,
RA   Shi E., Carter C., Venkov C., Yakes F.M., Page D.L., Lloyd R.S.,
RA   Mernaugh R.L., Hellerqvist C.G.;
RT   "Identification of a novel membrane protein, HP59, with therapeutic
RT   potential as a target of tumor angiogenesis.";
RL   Clin. Cancer Res. 7:4182-4194(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY,
RP   VARIANT SD CYS-39, AND VARIANTS ISSD 268-SER--ASN-272 DEL; ARG-183 AND
RP   ARG-334.
RX   PubMed=10581036; DOI=10.1038/70585;
RA   Verheijen F.W., Verbeek E., Aula N., Beerens C.E.M.T., Havelaar A.C.,
RA   Joosse M., Peltonen L., Aula P., Galjaard H., Van der Spek P.J.,
RA   Mancini G.M.S.;
RT   "A new gene, encoding an anion transporter, is mutated in sialic acid
RT   storage diseases.";
RL   Nat. Genet. 23:462-465(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   FUNCTION, DILEUCINE MOTIF, AND MUTAGENESIS OF 22-LEU--LEU-23.
RX   PubMed=15510212; DOI=10.1038/sj.emboj.7600464;
RA   Morin P., Sagne C., Gasnier B.;
RT   "Functional characterization of wild-type and mutant human sialin.";
RL   EMBO J. 23:4560-4570(2004).
RN   [7]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Placenta;
RX   PubMed=17897319; DOI=10.1111/j.1600-0854.2007.00643.x;
RA   Schroeder B., Wrocklage C., Pan C., Jaeger R., Koesters B.,
RA   Schaefer H., Elsaesser H.-P., Mann M., Hasilik A.;
RT   "Integral and associated lysosomal membrane proteins.";
RL   Traffic 8:1676-1686(2007).
RN   [8]
RP   TOPOLOGY, AND MUTAGENESIS OF PHE-179.
RX   PubMed=20424173; DOI=10.1074/jbc.M110.130716;
RA   Courville P., Quick M., Reimer R.J.;
RT   "Structure-function studies of the SLC17 transporter sialin identify
RT   crucial residues and substrate-induced conformational changes.";
RL   J. Biol. Chem. 285:19316-19323(2010).
RN   [9]
RP   FUNCTION, SUBCELLULAR LOCATION, AND VARIANT SD CYS-39.
RX   PubMed=21781115; DOI=10.1111/j.1471-4159.2011.07388.x;
RA   Miyaji T., Omote H., Moriyama Y.;
RT   "Functional characterization of vesicular excitatory amino acid
RT   transport by human sialin.";
RL   J. Neurochem. 119:1-5(2011).
RN   [10]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=22778404; DOI=10.1073/pnas.1116633109;
RA   Qin L., Liu X., Sun Q., Fan Z., Xia D., Ding G., Ong H.L., Adams D.,
RA   Gahl W.A., Zheng C., Qi S., Jin L., Zhang C., Gu L., He J., Deng D.,
RA   Ambudkar I.S., Wang S.;
RT   "Sialin (SLC17A5) functions as a nitrate transporter in the plasma
RT   membrane.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:13434-13439(2012).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-3, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [12]
RP   VARIANTS SD CYS-39 AND GLU-136, AND VARIANTS ISSD 268-SER--ASN-272
RP   DEL; ARG-183; ARG-334 AND VAL-371.
RX   PubMed=10947946; DOI=10.1086/303077;
RA   Aula N., Salomaeki P., Timonen R., Verheijen F., Mancini G.M.S.,
RA   Maensson J.-E., Aula P., Peltonen L.;
RT   "The spectrum of SLC17A5-gene mutations resulting in free sialic acid-
RT   storage diseases indicates some genotype-phenotype correlation.";
RL   Am. J. Hum. Genet. 67:832-840(2000).
RN   [13]
RP   VARIANT SD CYS-39.
RX   PubMed=12794687; DOI=10.1002/ajmg.a.10246;
RA   Martin R.A., Slaugh R., Natowicz M., Pearlman K., Orvisky E.,
RA   Krasnewich D., Kleta R., Huizing M., Gahl W.A.;
RT   "Sialic acid storage disease of the Salla phenotype in American
RT   monozygous twin female sibs.";
RL   Am. J. Med. Genet. A 120:23-27(2003).
CC   -!- FUNCTION: Transports glucuronic acid and free sialic acid out of
CC       the lysosome after it is cleaved from sialoglycoconjugates
CC       undergoing degradation, this is required for normal CNS
CC       myelination. Mediates aspartate and glutamate membrane potential-
CC       dependent uptake into synaptic vesicles and synaptic-like
CC       microvesicles. Also functions as an electrogenic 2NO(3)(-)/H(+)
CC       cotransporter in the plasma membrane of salivary gland acinar
CC       cells, mediating the physiological nitrate efflux, 25% of the
CC       circulating nitrate ions is typically removed and secreted in
CC       saliva. {ECO:0000269|PubMed:10581036, ECO:0000269|PubMed:11751519,
CC       ECO:0000269|PubMed:15510212, ECO:0000269|PubMed:21781115,
CC       ECO:0000269|PubMed:22778404}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:22778404};
CC       Multi-pass membrane protein {ECO:0000269|PubMed:22778404}.
CC       Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane
CC       {ECO:0000269|PubMed:21781115}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:21781115}. Lysosome membrane
CC       {ECO:0000269|PubMed:17897319}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:17897319}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9NRA2-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9NRA2-2; Sequence=VSP_010482, VSP_010483;
CC   -!- TISSUE SPECIFICITY: Found in fetal lung and small intestine, and
CC       at lower level in fetal skin and muscle. In the adult, detected in
CC       placenta, kidney and pancreas. Abundant in the endothelial cells
CC       of tumors from ovary, colon, breast and lung, but is not detected
CC       in endothelial cells from the corresponding normal tissues.
CC       {ECO:0000269|PubMed:10581036, ECO:0000269|PubMed:11751519}.
CC   -!- DISEASE: Salla disease (SD) [MIM:604369]: Sialic acid storage
CC       disease (SASD). SASDs are autosomal recessive neurodegenerative
CC       disorders characterized by hypotonia, cerebellar ataxia and mental
CC       retardation. They are caused by a defect in the metabolism of
CC       sialic acid which results in increased urinary excretion of
CC       unconjugated sialic acid, specifically N-acetylneuraminic acid.
CC       Enlarged lysosomes are seen on electron microscopic studies.
CC       Clinical symptoms of SD present usually at age less than 1 year
CC       and progression is slow. {ECO:0000269|PubMed:10581036,
CC       ECO:0000269|PubMed:10947946, ECO:0000269|PubMed:12794687,
CC       ECO:0000269|PubMed:21781115}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Infantile sialic acid storage disorder (ISSD)
CC       [MIM:269920]: Severe form of sialic acid storage disease. Affected
CC       newborns exhibit visceromegaly, coarse features and failure to
CC       thrive immediately after birth. These patients have a shortened
CC       life span, usually less than 2 years.
CC       {ECO:0000269|PubMed:10581036, ECO:0000269|PubMed:10947946}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the major facilitator superfamily.
CC       Sodium/anion cotransporter family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAF97769.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF244577; AAF97769.1; ALT_INIT; mRNA.
DR   EMBL; AJ387747; CAB62540.1; -; mRNA.
DR   EMBL; AK075320; BAC11546.1; -; mRNA.
DR   EMBL; AL590428; CAI15635.1; -; Genomic_DNA.
DR   EMBL; AL121972; CAI15635.1; JOINED; Genomic_DNA.
DR   EMBL; AL121972; CAI20417.1; -; Genomic_DNA.
DR   EMBL; AL590428; CAI20417.1; JOINED; Genomic_DNA.
DR   EMBL; BC020961; AAH20961.1; -; mRNA.
DR   CCDS; CCDS4981.1; -. [Q9NRA2-1]
DR   RefSeq; NP_036566.1; NM_012434.4. [Q9NRA2-1]
DR   UniGene; Hs.597422; -.
DR   ProteinModelPortal; Q9NRA2; -.
DR   BioGrid; 117710; 3.
DR   IntAct; Q9NRA2; 1.
DR   STRING; 9606.ENSP00000348019; -.
DR   TCDB; 2.A.1.14.10; the major facilitator superfamily (mfs).
DR   iPTMnet; Q9NRA2; -.
DR   PhosphoSitePlus; Q9NRA2; -.
DR   SwissPalm; Q9NRA2; -.
DR   BioMuta; SLC17A5; -.
DR   DMDM; 48428688; -.
DR   EPD; Q9NRA2; -.
DR   MaxQB; Q9NRA2; -.
DR   PaxDb; Q9NRA2; -.
DR   PeptideAtlas; Q9NRA2; -.
DR   PRIDE; Q9NRA2; -.
DR   DNASU; 26503; -.
DR   Ensembl; ENST00000355773; ENSP00000348019; ENSG00000119899. [Q9NRA2-1]
DR   GeneID; 26503; -.
DR   KEGG; hsa:26503; -.
DR   UCSC; uc003phn.5; human. [Q9NRA2-1]
DR   CTD; 26503; -.
DR   DisGeNET; 26503; -.
DR   GeneCards; SLC17A5; -.
DR   GeneReviews; SLC17A5; -.
DR   HGNC; HGNC:10933; SLC17A5.
DR   HPA; HPA044479; -.
DR   MalaCards; SLC17A5; -.
DR   MIM; 269920; phenotype.
DR   MIM; 604322; gene.
DR   MIM; 604369; phenotype.
DR   neXtProt; NX_Q9NRA2; -.
DR   OpenTargets; ENSG00000119899; -.
DR   Orphanet; 309324; Free sialic acid storage disease, infantile form.
DR   Orphanet; 309331; Intermediate severe Salla disease.
DR   Orphanet; 309334; Salla disease.
DR   PharmGKB; PA35824; -.
DR   eggNOG; KOG2532; Eukaryota.
DR   eggNOG; ENOG410XPWC; LUCA.
DR   GeneTree; ENSGT00760000119079; -.
DR   HOGENOM; HOG000230811; -.
DR   HOVERGEN; HBG008834; -.
DR   InParanoid; Q9NRA2; -.
DR   KO; K12301; -.
DR   OMA; RSSPNED; -.
DR   OrthoDB; EOG091G06DG; -.
DR   PhylomeDB; Q9NRA2; -.
DR   TreeFam; TF313535; -.
DR   Reactome; R-HSA-4085001; Sialic acid metabolism.
DR   Reactome; R-HSA-428643; Organic anion transporters.
DR   ChiTaRS; SLC17A5; human.
DR   GeneWiki; HP59; -.
DR   GeneWiki; SLC17A5; -.
DR   GenomeRNAi; 26503; -.
DR   PRO; PR:Q9NRA2; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000119899; -.
DR   CleanEx; HS_SLC17A5; -.
DR   Genevisible; Q9NRA2; HS.
DR   GO; GO:0030054; C:cell junction; IEA:UniProtKB-KW.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005765; C:lysosomal membrane; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0030672; C:synaptic vesicle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0015136; F:sialic acid transmembrane transporter activity; IDA:MGI.
DR   GO; GO:0015538; F:sialic acid:proton symporter activity; TAS:Reactome.
DR   GO; GO:0005351; F:sugar:proton symporter activity; TAS:ProtInc.
DR   GO; GO:0006865; P:amino acid transport; IEA:UniProtKB-KW.
DR   GO; GO:0006820; P:anion transport; TAS:ProtInc.
DR   GO; GO:0006811; P:ion transport; TAS:Reactome.
DR   GO; GO:0015739; P:sialic acid transport; IDA:MGI.
DR   CDD; cd06174; MFS; 1.
DR   InterPro; IPR011701; MFS.
DR   InterPro; IPR020846; MFS_dom.
DR   Pfam; PF07690; MFS_1; 1.
DR   SUPFAM; SSF103473; SSF103473; 2.
DR   PROSITE; PS50850; MFS; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Amino-acid transport; Cell junction;
KW   Cell membrane; Complete proteome; Cytoplasmic vesicle;
KW   Disease mutation; Glycoprotein; Lysosome; Membrane; Phosphoprotein;
KW   Reference proteome; Symport; Synapse; Transmembrane;
KW   Transmembrane helix; Transport.
FT   CHAIN         1    495       Sialin.
FT                                /FTId=PRO_0000220947.
FT   TOPO_DOM      1     41       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     42     62       Helical. {ECO:0000255}.
FT   TOPO_DOM     63    109       Lumenal. {ECO:0000255}.
FT   TRANSMEM    110    130       Helical. {ECO:0000255}.
FT   TOPO_DOM    131    136       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    137    157       Helical. {ECO:0000255}.
FT   TOPO_DOM    158    158       Lumenal. {ECO:0000255}.
FT   TRANSMEM    159    179       Helical. {ECO:0000255}.
FT   TOPO_DOM    180    200       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    201    221       Helical. {ECO:0000255}.
FT   TOPO_DOM    222    227       Lumenal. {ECO:0000255}.
FT   TRANSMEM    228    248       Helical. {ECO:0000255}.
FT   TOPO_DOM    249    279       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    280    300       Helical. {ECO:0000255}.
FT   TOPO_DOM    301    328       Lumenal. {ECO:0000255}.
FT   TRANSMEM    329    349       Helical. {ECO:0000255}.
FT   TOPO_DOM    350    365       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    366    386       Helical. {ECO:0000255}.
FT   TOPO_DOM    387    391       Lumenal. {ECO:0000255}.
FT   TRANSMEM    392    412       Helical. {ECO:0000255}.
FT   TOPO_DOM    413    423       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    424    444       Helical. {ECO:0000255}.
FT   TOPO_DOM    445    457       Lumenal. {ECO:0000255}.
FT   TRANSMEM    458    478       Helical. {ECO:0000255}.
FT   TOPO_DOM    479    495       Cytoplasmic. {ECO:0000255}.
FT   MOTIF        22     23       Dileucine internalization motif.
FT   MOD_RES       3      3       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   CARBOHYD     71     71       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD     77     77       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD     95     95       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   VAR_SEQ     274    276       LSS -> AGV (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_010482.
FT   VAR_SEQ     278    495       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_010483.
FT   VARIANT      39     39       R -> C (in SD; completely devoid of
FT                                aspartate and glutamate transport
FT                                activity, but retains appreciable H(+)/
FT                                sialic acid cotransport activity,
FT                                frequent mutation in Finland;
FT                                dbSNP:rs80338794).
FT                                {ECO:0000269|PubMed:10581036,
FT                                ECO:0000269|PubMed:10947946,
FT                                ECO:0000269|PubMed:12794687,
FT                                ECO:0000269|PubMed:21781115}.
FT                                /FTId=VAR_018684.
FT   VARIANT     136    136       K -> E (in SD; dbSNP:rs80338795).
FT                                {ECO:0000269|PubMed:10947946}.
FT                                /FTId=VAR_018685.
FT   VARIANT     183    183       H -> R (in ISSD; dbSNP:rs119491109).
FT                                {ECO:0000269|PubMed:10581036,
FT                                ECO:0000269|PubMed:10947946}.
FT                                /FTId=VAR_018686.
FT   VARIANT     268    272       Missing (in ISSD).
FT                                {ECO:0000269|PubMed:10581036,
FT                                ECO:0000269|PubMed:10947946}.
FT                                /FTId=VAR_018687.
FT   VARIANT     296    296       V -> I (in dbSNP:rs16883930).
FT                                /FTId=VAR_034746.
FT   VARIANT     334    334       P -> R (in ISSD; dbSNP:rs119491110).
FT                                {ECO:0000269|PubMed:10581036,
FT                                ECO:0000269|PubMed:10947946}.
FT                                /FTId=VAR_018688.
FT   VARIANT     371    371       G -> V (in ISSD).
FT                                {ECO:0000269|PubMed:10947946}.
FT                                /FTId=VAR_018689.
FT   MUTAGEN      22     23       LL->GG: Targeted to plasma membrane;
FT                                sialic acid uptake strongly activated at
FT                                acidic pH. {ECO:0000269|PubMed:15510212}.
FT   MUTAGEN     179    179       F->C: 15 fold increase in affinity for
FT                                glucuronic acid.
FT                                {ECO:0000269|PubMed:20424173}.
SQ   SEQUENCE   495 AA;  54640 MW;  5C6C154B3E93A19E CRC64;
     MRSPVRDLAR NDGEESTDRT PLLPGAPRAE AAPVCCSARY NLAILAFFGF FIVYALRVNL
     SVALVDMVDS NTTLEDNRTS KACPEHSAPI KVHHNQTGKK YQWDAETQGW ILGSFFYGYI
     ITQIPGGYVA SKIGGKMLLG FGILGTAVLT LFTPIAADLG VGPLIVLRAL EGLGEGVTFP
     AMHAMWSSWA PPLERSKLLS ISYAGAQLGT VISLPLSGII CYYMNWTYVF YFFGTIGIFW
     FLLWIWLVSD TPQKHKRISH YEKEYILSSL RNQLSSQKSV PWVPILKSLP LWAIVVAHFS
     YNWTFYTLLT LLPTYMKEIL RFNVQENGFL SSLPYLGSWL CMILSGQAAD NLRAKWNFST
     LCVRRIFSLI GMIGPAVFLV AAGFIGCDYS LAVAFLTIST TLGGFCSSGF SINHLDIAPS
     YAGILLGITN TFATIPGMVG PVIAKSLTPD NTVGEWQTVF YIAAAINVFG AIFFTLFAKG
     EVQNWALNDH HGHRH
//
